اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,766
تعداد مقالات31,497
تعداد مشاهده مقاله39,698,982
تعداد دریافت فایل اصل مقاله17,254,063
Nesterova, N. I, Pokrovskii, V. V, Patrakhanov, E. A, Pirozhkov, I. V, Pokrovskaya, T. G, Levit, N. B, M.I, I, Kizi, S. N. M., Nesterov, A. V, Shutov, V. I, Yuri A. Hoshchenko, Y. (1400). Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats. سامانه مدیریت نشریات علمی, 76(4), 1025-1034. doi: 10.22092/ari.2021.355813.1723
N. I Nesterova; V. V Pokrovskii; E. A Patrakhanov; I. V Pirozhkov; T. G Pokrovskaya; N. B Levit; I M.I; S. N. M. Kizi; A. V Nesterov; V. I Shutov; Y Yuri A. Hoshchenko. "Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats". سامانه مدیریت نشریات علمی, 76, 4, 1400, 1025-1034. doi: 10.22092/ari.2021.355813.1723
Nesterova, N. I, Pokrovskii, V. V, Patrakhanov, E. A, Pirozhkov, I. V, Pokrovskaya, T. G, Levit, N. B, M.I, I, Kizi, S. N. M., Nesterov, A. V, Shutov, V. I, Yuri A. Hoshchenko, Y. (1400). 'Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats', سامانه مدیریت نشریات علمی, 76(4), pp. 1025-1034. doi: 10.22092/ari.2021.355813.1723
Nesterova, N. I, Pokrovskii, V. V, Patrakhanov, E. A, Pirozhkov, I. V, Pokrovskaya, T. G, Levit, N. B, M.I, I, Kizi, S. N. M., Nesterov, A. V, Shutov, V. I, Yuri A. Hoshchenko, Y. Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats. سامانه مدیریت نشریات علمی, 1400; 76(4): 1025-1034. doi: 10.22092/ari.2021.355813.1723

Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats

Archives of Razi Institute
مقاله 32، دوره 76، شماره 4، آذر و دی 2021، صفحه 1025-1034    اصل مقاله (619.73 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355813.1723
نویسندگان
N. I Nesterova* 1؛ V. V Pokrovskii2؛ E. A Patrakhanov2؛ I. V Pirozhkov1؛ T. G Pokrovskaya2؛ N. B Levit1؛ I M.I2؛ S. N. M. Kizi2؛ A. V Nesterov1؛ V. I Shutov3؛ Y Yuri A. Hoshchenko2
1Regional State Funded Healthcare Facility “Belgorod Forensic Medical Bureau”, 159, Volchanskaya St., Belgorod, 308017, Russia
2Belgorod State National Research University, 85, Pobeda St., Belgorod, 308015, Russia
3Belgorod Regional Hospital of St. Joasaph, 8/9, Nekrasova St., Belgorod, 308036, Russia
چکیده
Sudden loss of blood flow to an area of the brain causes ischemic stroke, which leads to the loss of nerve function in the brain. The brain tissue leads to the death of brain cells in less than a few minutes due to the lack of oxygen and nutrients. This study aimed to evaluate the effectiveness of pharmacological correction of the consequences of ischemic stroke with a new derivative of taurine magnesium-bis-(2-aminoethanesulfonic)-butanedioate under laboratory code LKHT 3-17 in rats. The ischemic stroke was simulated by electrocoagulation of the right middle cerebral artery. The assessment of lethality, neurological status, locomotor, exploratory behavior, and morphological pattern of the brain damage was carried out on the 1st, 3rd, and 7th day after the pathology simulation. Neurological deficit was determined by the McGrow stroke index scale. The locomotor and exploratory behavior was evaluated using the Acti-track software and hardware complex. When assessing the morphological changes in the brain, attention was paid to two criteria, including the average thickness of the brain cortex and the number of neurons without degenerative changes. The substances were administered 60 minutes before the start of surgery. The animals were divided into an intact group (n=20); ischemic stroke simulation group without pharmacological correction (n=50); a group with correction of the ischemic stroke with taurine at the dose of 50 mg/kg (n=50); and a group with correction of ischemic stroke with magnesium-bis-(2-aminoethanesulfonic)-butadioate (LKHT 3-17) at the dose of 150 mg/kg (n=50).LHT 3-17 (150 mg/kg) and taurine (50 mg/kg) reduced lethality by 1.55 and 1.47 times, respectively, on the 7th day after stroke, compared to the control group (P<0.05). In parallel, an effective correction of neurological deficit was found for LKHT 3-17 and taurine to 4.0±0.8 and 7.6±0.9, respectively, on the 3rd day in contrast to the control of 8.1±0.8 points. The locomotor and exploratory behavior was most significantly different on the 1st and 7th days and was accompanied by a significant increase in the speed of movement under the influence of LKHT3-17 to 20 and 20 conventional units, compared to the control of 7 and 5 cu. On the 1st day, the thickness of the cortex was 1877.3±43.3 µm in the control group, and 1531.8±39.1 µm in the LKHT 3-17 group. The number of neurons without neurodegenerative changes prevailed in the group administered with LHT 3-17 (19.3±4.3), and the lowest number was observed in the group without pharmacological correction of the pathology (14.3±3.7).LKHT 3-17 at a dose of 150 mg/kg is more effective than taurine 50 mg/kg in protecting nerve activity in experimental ischemic stroke and reducing lethality, minimizing nerve defects, reducing volume, accelerating the process of tissue repair, helping stroke, and activating the regenerative processes.
کلیدواژه‌ها
Ischemic Stroke؛ Neuroprotection؛ Taurine
سایر فایل های مرتبط با مقاله
مراجع
  1. Starodubov VI, Marczak LB, Varavikova E, Bikbov B, Ermakov SP, Gall J, et al. The burden of disease in Russia from 1980 to 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10153):1138-46.
  2. S Pandya R, Mao L, Zhou H, Zhou S, Zeng J, John Popp A, et al. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem. 2011;11(2):81-97.
  3. Beskhmelnitsyna EA, Pokrovskii MV, Kulikov AL, Peresypkina AA, Varavin EI. Study of Anti-inflammatory Activity of a New Non-opioid Analgesic on the Basis of a Selective Inhibitor of TRPA1 Ion Channels. Antiinflamm Antiallergy Agents Med Chem. 2019;18(2):110-25.
  4. Bezverkhniaia EA, Povet’eva TN, Kadyrova TV, Suslov NI, Nesterova YV, Ol’ga G, et al. Screening study for anticonvulsive activity of lipophilic fractions from empetrum nigrum L. Res Results Pharmacol. 2020;6:67.
  5. Peresypkina A, Pazhinsky A, Pokrovskii M, Beskhmelnitsyna E, Pobeda A, Korokin M. Correction of experimental retinal ischemia by l-isomer of ethylmethylhydroxypyridine malate. Antioxidants. 2019;8(2):34.
  6. Schaffer S, Kim HW. Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther 2018;26(3):225.
  7. Iu GO. Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205. Res Results Pharmacol. 2020;6(3).
  8. Abramets II, Kuznetsov YV, Evdokimov DV, Zayka TO. Piracetam potentiates neuronal and behavioral effects of ketamine. Res Results Pharmacol. 2019;5(2):49-55.
  9. Avdeeva NV, Sidorova SA, Gudyrev OS, Ol'ga AO, Golubev IV. Mechanism of neuroprotective effect of mGluR4 agonists. Res Results Pharmacol. 2019;5:43.
  10. Galenko-Yaroshevsky PA, Popkov VL, Bedrosova KA, Faustov LA, Sukoyan GV. Benzofurocaine: effects on experimental periodontitis, anti-diabetic activity and molecular mechanisms of action. Res Results Pharmacol. 2019;5(1)15-30.
  11. Lebedev AA, Bessolova YN, Efimov NS, Bychkov ER, Droblenkov AV, Shabanov PD. Role of orexin peptide system in emotional overeating induced by brain reward stimulation in fed rats. Res Results Pharmacol. 2020;6(1).
  12. Ripps H, Shen W. taurine: a “very essential” amino acid. Mol Vis. 2012;18:2673.
  13. Bkaily G, Jazzar A, Normand A, Simon Y, Al-Khoury J, Jacques D. Taurine and cardiac disease: state of the art and perspectives. Can J Physiol Pharmacol. 2020;98(2):67-73.
  14. Trofimenko AI, Kade AKh, Lebedev VP, Zanin SA, VV M. Modeling of Cerebral Ischemia by Coagulation of the Middle Cerebral Artery In Rats. 2012;2:215-8.
  15. McGraw CP, Pashayan A, Wendel O. Cerebral infarction in the Mongolian gerbil exacerbated by phenoxybenzamine treatment. Stroke. 1976;7(5):485-8.
  16. Chen N, Xu RJ, Wang LL, Zhang M, Feng SC, Zhou JY, et al. Protective effects of magnesium sulfate on radiation induced brain injury in rats. Curr Drug Deliv. 2018;15(8):1159-66.
  17. Imer M, Omay B, Uzunkol A, Erdem T, Sabanci PA, Karasu A, et al. Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood–brain barrier permeability and brain edema after experimental traumatic diffuse brain injury. Neurol Res. 2009;31(9):977-81.
  18. Ghabriel M, Thomas A, Vink R. Magnesium restores altered aquaporin-4 immunoreactivity following traumatic brain injury to a pre-injury state. Brain Edema XIII: Springer; 2006. p. 402-6.
  19. Pan C, Giraldo GS, Prentice H, Wu J-Y. Taurine protection of PC12 cells against endoplasmic reticulum stress induced by oxidative stress. J Biomed Sci. 2010;17(1):1-7.
  20. Ginguay A, De Bandt J-P, Cynober L. Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness. Curr Opin Clin Nutr Metab Care. 2016;19(2):161-9.
  21. Oja SS, Saransaari P. Modulation of taurine release by glutamate receptors and nitric oxide. Prog Neurobiol. 2000;62(4):407-25.
  1. Wu J-Y, Prentice H. Role of taurine in the central nervous system. J Biomed Sci. 2010;17(1):1-6.
  2. Ricci L, Valoti M, Sgaragli G, Frosini M. Protection by taurine of rat brain cortical slices against oxygen glucose deprivation-and reoxygenation-induced damage. Eur J Pharmacol. 2009;621(1-3):26-32.
  3. Kaya M, Kalayci R, Küçük M, Arican N, Elmas I, Kudat H, et al. Effect of losartan on the blood–brain barrier permeability in diabetic hypertensive rats. Life Sci. 2003;73(25):3235-44.
  4. Zarzhetsky SE, Mutuskina EA, IE T. The effect of sodium succinate on the functional, biochemical, and morphological parameters of CNS recovery in rats after a 10-minute circulatory arrest. Anaesthesiol Reanimatol. 1994;5:96-103.
26.          Nechipurenko NI, Vasilevskaya LA, TV G. Efficacy of mexidol in experimental cerebral ischemia. Byullexper Biol I Med. 2006:224-9.

آمار
تعداد مشاهده مقاله: 1,025
تعداد دریافت فایل اصل مقاله: 337


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب